Table 2.
Pre-bronchoscopy, post-bronchoscopy, and final diagnosis (N = 245)
| Pre-bronchoscopy diagnosis N (%)a |
Post-bronchoscopy diagnosis N (%)b |
Final diagnosis N (%)c |
|
|---|---|---|---|
| IPF | 22 (9.0) | 19 (7.8)d | 20 (8.2) |
| HP | 18 (7.3) | 69 (28.2) | 97 (39.6) |
| CTD-ILD | 45 (18.4) | 45 (18.4) | 45 (18.4) |
| IPAF | 19 (7.8) | 19 (7.8) | 21 (8.6) |
| Unclassifiable | 122 (49.8) | 68 (27.8) | 27 (11.0) |
| Drug-induced | 6 (2.4) | 6 (2.4) | 6 (2.4) |
| IPPFE | 0 (0) | 0 (0) | 1 (0.4) |
| RB-ILD or DIP | 1 (0.4) | 1 (0.4) | 2 (0.8) |
| Idiopathic NSIP | 3 (1.2) | 3 (1.2) | 4 (1.6) |
| COP | 6 (2.4) | 6 (2.4) | 6 (2.4) |
| Idiopathic bronchiolitis | 0 (0) | 0 (0) | 2 (0.8) |
| Chronic eosinophilic pneumonia | 0 (0) | 2 (0.8) | 2 (0.8) |
| Pulmonary alveolar proteinosis | 0 (0) | 1 (0.4) | 1 (0.4) |
| Amyloid | 0 (0) | 1 (0.4) | 1 (0.4) |
| Primary biliary cirrhosis | 0 (0) | 1 (0.4) | 1 (0.4) |
| ANCA vasculitis | 0 (0) | 1 (0.4) | 3 (1.2) |
| Pulmonary alveolar microlithiasis | 1 (0.4) | 1 (0.4) | 1 (0.4) |
| Surfactant protein C deficiency | 0 (0) | 0 (0) | 1 (0.4) |
| Langerhans cell histiocytosis | 0 (0) | 0 (0) | 1 (0.4) |
| Inflammatory bowel disease | 1 (0.4) | 1 (0.4) | 1 (0.4) |
| Post-ARDS fibrosis | 0 (0) | 0 (0) | 1 (0.4) |
| Hypereosinophilic syndrome | 1 (0.4) | 1 (0.4) | 1 (0.4) |
IPF idiopathic pulmonary fibrosis, HP hypersensitivity pneumonitis, CTD-ILD connective tissue disease-related interstitial lung disease, IPAF interstitial pneumonia with autoimmune features, IPPFE idiopathic pleuroparenchymal fibroelastosis, RB-ILD respiratory bronchiolitis interstitial lung disease, DIP desquamative interstitial pneumonia, NSIP non-specific interstitial pneumonia, COP cryptogenic organizing pneumonia, ANCA antineutrophil cytoplasmic antibody, ARDS adult respiratory distress syndrome
Pre-bronchoscopy diagnosis takes into account the history, examination, serologic studies, and initial HRCT results
Post-bronchoscopy diagnosis takes into account the history, examination, serologic studies, initial HRCT, and bronchoscopy results
Final diagnosis takes into account the history, examination, serologic studies, initial and subsequent HRCT, bronchoscopy, SLB, and explant results
4 patients with a pre-bronchoscopy diagnosis of IPF received a post-bronchoscopy diagnosis of HP, and 1 patient with a pre-bronchoscopy diagnosis of unclassifiable ILD received a post-bronchoscopy diagnosis of IPF based on the presence of fibroblastic foci on transbronchial biopsy. Therefore, there were 3 net fewer IPF diagnosis post-bronchoscopy compared to pre-bronchoscopy